"MDMA's Potential FDA Approval for PTSD Therapy by 2024"

A recent study sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) suggests that MDMA, commonly known as Ecstasy or Molly, can effectively reduce symptoms of post-traumatic stress disorder (PTSD). The study involved 104 participants with PTSD who were randomly assigned to receive either MDMA or a placebo pill during three therapy sessions. Results showed that 86% of the MDMA group experienced improvement in PTSD symptoms compared to 69% in the placebo group. Additionally, 72% of the MDMA group no longer met the criteria for a PTSD diagnosis after the study. The therapy could potentially be approved by the FDA by 2024, following further research and evaluation.